Autologous T-cells Transfected With mRNA Encoding HBV-TCR T Cell Therapy in Combination With NUC for Chronic Hepatitis B

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

June 1, 2023

Primary Completion Date

June 30, 2025

Study Completion Date

June 30, 2026

Conditions
Chronic Hepatitis B
Interventions
BIOLOGICAL

TCR-T

"Stage-1: Patients will receive three biweekly HBV-TCR T cell infusions at escalating doses, ranging from 1 x 10\^5 cells/kg to 5 x 10\^6 cells/kg bodyweight (by IV infusion). Patients are to remain on existing HBV NUC treatment.~Stage-2: Patients will receive three biweekly HBV-TCR T cell infusions at maximum dose as determined in Stage-1 study. Patients are to remain on existing HBV NUC treatment."

Trial Locations (1)

100039

The Fifth Medical Center of PLA General Hospital, Beijing

All Listed Sponsors
lead

Beijing 302 Hospital

OTHER